Novel Insights into the Links between N6-Methyladenosine and Regulated Cell Death in Musculoskeletal Diseases DOI Creative Commons
Juanjuan Han, C Wang, Haolin Yang

и другие.

Biomolecules, Год журнала: 2024, Номер 14(5), С. 514 - 514

Опубликована: Апрель 24, 2024

Musculoskeletal diseases (MSDs), including osteoarthritis (OA), osteosarcoma (OS), multiple myeloma (MM), intervertebral disc degeneration (IDD), osteoporosis (OP), and rheumatoid arthritis (RA), present noteworthy obstacles associated with pain, disability, impaired quality of life on a global scale. In recent years, it has become increasingly apparent that N6-methyladenosine (m6A) is key regulator in the expression genes multitude biological processes. m6A composed 0.1–0.4% adenylate residues, especially at beginning 3′-UTR near translation stop codon. The can be classified into three types, namely “writer”, “reader”, “eraser”. Studies have shown epigenetic modulation influences mRNA processing, nuclear export, translation, splicing. Regulated cell death (RCD) autonomous orderly cells under genetic control to maintain stability internal environment. Moreover, distorted RCDs are widely used influence course various receiving increasing attention from researchers. past few evidence indicated regulate gene thus different RCD processes, which central role etiology evolution MSDs. currently confirmed autophagy-dependent death, apoptosis, necroptosis, pyroptosis, ferroptosis, immunogenic NETotic oxeiptosis. m6A–RCD axis inflammatory response chondrocytes invasive migratory MM bone remodeling capacity, thereby influencing development This review gives complete overview regulatory functions across muscle, bone, cartilage. addition, we also discuss advances by m6A-targeted factors explore clinical application prospects therapies targeting MSD prevention treatment. These may provide new ideas directions for understanding pathophysiological mechanism MSDs treatment these diseases.

Язык: Английский

Circulating small extracellular vesicle-encapsulated SEMA5A-IT1 attenuates myocardial ischemia–reperfusion injury after cardiac surgery with cardiopulmonary bypass DOI Creative Commons
Ting Wu,

Guoning Shi,

Zhenhua Ji

и другие.

Cellular & Molecular Biology Letters, Год журнала: 2022, Номер 27(1)

Опубликована: Окт. 25, 2022

Cardiomyocyte injury is a common complication during cardiac surgery with cardiopulmonary bypass (CPB). Studies have shown that circulating small extracellular vesicles (sEVs) are involved in the pathological process of cardiovascular diseases via delivering signaling molecules. This study aims to investigate relationship between sEV-encapsulated long noncoding RNAs (lncRNAs) and after CPB. Here, we found expression sEV SEMA5A-IT1 serum samples patients CPB was higher than pre-CPB samples. Moreover, serum-derived levels were negatively correlated creatine kinase-MB (CK-MB) who underwent operation. Notably, sEVs packaged could be uptaken by cardiomyocyte-like cells AC16 increased cells. Upregulated protected cardiomyocytes against hypoxia/reoxygenation injury, confirmed cell viability, reduced apoptosis, inhibited ferroptosis Mechanistically, regulated B-cell CLL/lymphoma 2 (BCL2) solute carrier family 7 member 11 (SLC7A11) through sponging miR-143-3p. Transfection miR-143-3p mimics, BCL2, or SLC7A11 knockdown attenuate protective effect on cardiomyocytes. In conclusion, propose SEMA5A-IT1, which transported sEVs, an important regulatory molecule protects from ischemia-reperfusion providing target for prevention treatment myocardial injury.

Язык: Английский

Процитировано

25
Novel insights into the interplay between m6A modification and programmed cell death in cancer DOI Creative Commons
Jinhao Chen, Mujie Ye, Jian’an Bai

и другие.

International Journal of Biological Sciences, Год журнала: 2023, Номер 19(6), С. 1748 - 1763

Опубликована: Янв. 1, 2023

N6-methyladenosine (m6A) methylation, the most prevalent and abundant RNA modification in eukaryotes, has recently become a hot research topic.Several studies have indicated that m6A is dysregulated during progression of multiple diseases, especially cancer development.Programmed cell death (PCD) an active orderly method development organisms, including apoptosis, autophagy, pyroptosis, ferroptosis, necroptosis.As study PCD increasingly profound, accumulating evidence revealed mutual regulation PCD, their interaction can further influence sensitivity treatment.In this review, we summarize recent advances terms interplay potential mechanisms, as well therapeutic resistance.Our provides promising insights future directions for examination treatment cancers.

Язык: Английский

Процитировано

16
m6A control programmed cell death in cardiac fibrosis DOI
Zhenyu Liu,

Qing-Ye You,

Zhiyan Liu

и другие.

Life Sciences, Год журнала: 2024, Номер 353, С. 122922 - 122922

Опубликована: Июль 18, 2024

Язык: Английский

Процитировано

5
Klf6 aggravates myocardial ischemia/reperfusion injury by activating Acsl4‐mediated ferroptosis DOI Creative Commons

Mali Qiu,

Wei Yan,

M. Liu

и другие.

The Kaohsiung Journal of Medical Sciences, Год журнала: 2023, Номер 39(10), С. 989 - 1001

Опубликована: Авг. 2, 2023

Abstract Ferroptosis is closely related to myocardial ischemia/reperfusion (I/R) damage. Kruppel‐like factor 6 (Klf6) can aggravate renal I/R injury. We aimed elucidate the role of Klf6 in damage as well its potential mechanism. Myocardial mice model and hypoxia/reoxygenation (H/R)‐treated HL‐1 cells were established. The levels Fe 2+ , MDA, lipid ROS, ferroptosis‐related proteins measured for assessing ferroptosis. Infarct area, H&E staining, cardiac function, cell viability detected evaluating Immunohistochemistry, immunofluorescence, western blot, RT‐qPCR applied detecting genes. m6A modification Klf6, relationships between Mettl3, Igf2bp2, or Acsl4 promoter, was evaluated using MeRIP, RNA immunoprecipitation, pull‐down, chromatin luciferase reporter assay accordingly.Klf6 protein mRNA levels, modification, elevated subjected H/R heart tissues from mice. In H/R‐challenged cells, binding Igf2bp2 Mettl3 confirmed; moreover, knockdown decreased level inhibited stability. restrained H/R‐triggered loss, improved I/R‐induced injury, ferroptosis models. directly bound promoter positively regulated expression. overexpression compromised knockdown‐generated protective effect cells.m6A modification‐regulated aggravated through activating Acsl4‐mediated ferroptosis, thereby providing one target treatment I/R.

Язык: Английский

Процитировано

12
METTL3: a multifunctional regulator in diseases DOI
Na Li, Wei Xiang,

J.J. Dai

и другие.

Molecular and Cellular Biochemistry, Год журнала: 2025, Номер unknown

Опубликована: Янв. 24, 2025

Язык: Английский

Процитировано

0
Novel Insight of N6-Methyladenosine in Cardiovascular System DOI Creative Commons
Huan Zhang, Wei Lu,

Hao-Yue Tang

и другие.

Medicina, Год журнала: 2025, Номер 61(2), С. 222 - 222

Опубликована: Янв. 26, 2025

N6-methyladenosine (m6A) is the most common and abundant internal co-transcriptional modification in eukaryotic RNAs. This catalyzed by m6A methyltransferases, known as “writers”, including METTL3/14 WTAP, removed demethylases, or “erasers”, such FTO ALKBH5. It recognized m6A-binding proteins, “readers”, YTHDF1/2/3, YTHDC1/2, IGF2BP1/2/3, HNRNPA2B1. Cardiovascular diseases (CVDs) are leading cause of morbidity mortality worldwide. Recent studies indicate that RNA plays a critical role both physiological pathological processes involved initiation progression CVDs. In this review, we will explore how methylation impacts normal disease states cardiovascular system. Our focus be on recent advancements understanding biological functions, molecular mechanisms, regulatory factors methylation, along with its downstream target genes various CVDs, atherosclerosis, ischemic diseases, metabolic disorders, heart failure. We propose pathway holds promise potential therapeutic disease.

Язык: Английский

Процитировано

0
The Emerging Role of m6A and Programmed Cell Death in Cardiovascular Diseases DOI Creative Commons
Haixia Wang, Juanjuan Han, Hui Kong

и другие.

Biomolecules, Год журнала: 2025, Номер 15(2), С. 247 - 247

Опубликована: Фев. 8, 2025

N6-methyladenosine (m6A) is the most prevalent internal chemical modification in eukaryotic messenger RNA (mRNA), significantly impacting its lifecycle through dynamic and reversible processes involving methyltransferase, demethylase, binding proteins. These regulate mRNA stability, splicing, nuclear export, translation, degradation. Programmed cell death (PCD), a tightly controlled process encompassing apoptosis, pyroptosis, ferroptosis, autophagy, necroptosis, plays crucial role maintaining cellular homeostasis, tissue development, function. Recently, m6A has emerged as significant research area due to regulating PCD implications cardiovascular diseases (CVDs). In this review, we delve into intricate relationship between various types modification, emphasizing their pivotal roles initiation progression of CVDs such myocardial ischemia-reperfusion (I/R), atherosclerosis (AS), pulmonary hypertension (PH), cardiomyopathy, doxorubicin (Dox)-induced cardiotoxicity (DIC), heart failure (HF), infarction (MI). Our findings underscore potential elucidating CVD pave new pathways for prevention treatment strategies.

Язык: Английский

Процитировано

0
METTL3 mediates CPB1 expression by regulating transcription factor BACH2 to promote apoptosis and oxidative stress of lens epithelial cells DOI
Sheng Zhao, Yu Pan,

Shao Li-qin

и другие.

Journal of Bioenergetics and Biomembranes, Год журнала: 2025, Номер unknown

Опубликована: Фев. 21, 2025

Язык: Английский

Процитировано

0
A comprehensive review of m6 A methylation in coronary heart disease DOI
Mei-Ning Diao, Yingli Lv, Xin Hui

и другие.

Journal of Molecular Medicine, Год журнала: 2025, Номер unknown

Опубликована: Апрель 10, 2025

Язык: Английский

Процитировано

0
Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases DOI Creative Commons
Vilbert Sikorski,

Antti Vento,

Esko Kankuri

и другие.

Molecular Therapy — Nucleic Acids, Год журнала: 2022, Номер 29, С. 426 - 461

Опубликована: Июль 20, 2022

Cardiovascular diseases lead the mortality and morbidity disease metrics worldwide. A multitude of chemical base modifications in ribonucleic acids (RNAs) have been linked with key events cardiovascular metabolic disorders. Named either RNA epigenetics or epitranscriptomics, post-transcriptional modifications, their regulatory pathways, components, downstream effects substantially contribute to ways our genetic code is interpreted. Here we review accumulated discoveries date regarding roles two most common epitranscriptomic N6-methyl-adenosine (m6A) adenosine-to-inosine (A-to-I) editing, disease.

Язык: Английский

Процитировано

16